Home/Filings/4/0001209191-23-016391
4//SEC Filing

Fontenot Jason D. 4

Accession 0001209191-23-016391

CIK 0001001233other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 5:07 PM ET

Size

10.9 KB

Accession

0001209191-23-016391

Insider Transaction Report

Form 4
Period: 2023-02-24
Fontenot Jason D.
SVP, Chief Scientific Officer
Transactions
  • Tax Payment

    Common Stock

    2023-02-25$2.66/sh6,559$17,447139,358 total
  • Award

    Stock Option (Right to Buy)

    2023-02-24+199,500199,500 total
    Exercise: $2.66Exp: 2033-02-23Common Stock (199,500 underlying)
  • Award

    Common Stock

    2023-02-24+42,750145,917 total
Footnotes (4)
  • [F1]Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
  • [F2]Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
  • [F3]Includes: (a) 6,306 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 5,548 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 7,344 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, and (c) 8,530 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 33,825 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
  • [F4]One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Issuer

SANGAMO THERAPEUTICS, INC

CIK 0001001233

Entity typeother

Related Parties

1
  • filerCIK 0001851761

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 5:07 PM ET
Size
10.9 KB